TACSTD2 and prostate cancer: Given our finding that elevated tissue levels of Trop2 were associated with poorer clinical features, we assessed whether shed Trop2 could be detected in the urine from men with clinically significant prostate cancer, thereby providing a non-invasive biomarker to identify clinically significant prostate cancer and monitor the disease.